Literature DB >> 27481447

Practice Patterns and Preferences Among Hematopoietic Cell Transplantation Clinicians.

William A Wood1, Margaret K McGinn2, Doug Wilson2, Allison M Deal2, Nandita Khera3, Thomas C Shea2, Steven M Devine4, Frederick R Appelbaum5, Mary M Horowitz6, Stephanie J Lee5.   

Abstract

Hematopoietic cell transplantation can cure many high-risk diseases but is associated with complexity, cost, and risk. Several areas in transplantation practice were identified in the 2014 Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium (BMT CTN SOSS) as high priorities for further study. We developed a survey for hematopoietic cell transplantation clinicians to identify current practices in BMT CTN SOSS priority areas and to understand, more generally, the variation in approach to transplantation and estimation of transplantation benefit in current medical practice. Of 1439 transplantation clinicians surveyed, 305 responded (20% response rate). Clinicians were well represented by age, experience, geography, and size of practice. We found that several techniques identified in the BMT CTN SOSS, such as maintenance therapy for acute myeloid leukemia or myelodysplastic syndromes after allogeneic transplantation, were already being utilized in practice on and off study, with higher rates of use in higher-volume centers. There was significant variation among clinicians in use of transplantation technologies and approaches to common transplantation scenarios. Appraisals of risks and benefits of transplantation appeared to converge upon similar estimates despite the presentation of different hypothetical scenarios. These results suggest overall equipoise in several BMT CTN SOSS high-priority areas and support the need for better data to inform clinical practice.
Copyright © 2016 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diffusion of innovations; Hematopoietic cell transplantation; Practice patterns; Survey; Technology

Mesh:

Year:  2016        PMID: 27481447      PMCID: PMC5067220          DOI: 10.1016/j.bbmt.2016.07.014

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  17 in total

1.  R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.

Authors:  Antonio Omuro; Denise D Correa; Lisa M DeAngelis; Craig H Moskowitz; Matthew J Matasar; Thomas J Kaley; Igor T Gavrilovic; Craig Nolan; Elena Pentsova; Christian C Grommes; Katherine S Panageas; Raymond E Baser; Geraldine Faivre; Lauren E Abrey; Craig S Sauter
Journal:  Blood       Date:  2015-01-07       Impact factor: 22.113

2.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

3.  Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902).

Authors:  William A Wood; Jennifer Le-Rademacher; Karen L Syrjala; Heather Jim; Paul B Jacobsen; Jennifer M Knight; Muneer H Abidi; John R Wingard; Navneet S Majhail; Nancy L Geller; J Douglas Rizzo; Mingwei Fei; Juan Wu; Mary M Horowitz; Stephanie J Lee
Journal:  Cancer       Date:  2015-10-06       Impact factor: 6.860

4.  Blood and marrow transplant clinical trials network state of the Science Symposium 2014.

Authors:  Frederick R Appelbaum; Claudio Anasetti; Joseph H Antin; Harold Atkins; Stella Davies; Steven Devine; Sergio Giralt; Helen Heslop; Ginna Laport; Stephanie J Lee; Brent Logan; Marcelo Pasquini; Michael Pulsipher; Edward Stadtmauer; John R Wingard; Mary M Horowitz
Journal:  Biol Blood Marrow Transplant       Date:  2014-10-15       Impact factor: 5.742

5.  Peripheral-blood stem cells versus bone marrow from unrelated donors.

Authors:  Claudio Anasetti; Brent R Logan; Stephanie J Lee; Edmund K Waller; Daniel J Weisdorf; John R Wingard; Corey S Cutler; Peter Westervelt; Ann Woolfrey; Stephen Couban; Gerhard Ehninger; Laura Johnston; Richard T Maziarz; Michael A Pulsipher; David L Porter; Shin Mineishi; John M McCarty; Shakila P Khan; Paolo Anderlini; William I Bensinger; Susan F Leitman; Scott D Rowley; Christopher Bredeson; Shelly L Carter; Mary M Horowitz; Dennis L Confer
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

6.  A risk score for mortality after allogeneic hematopoietic cell transplantation.

Authors:  Tanyalak Parimon; David H Au; Paul J Martin; Jason W Chien
Journal:  Ann Intern Med       Date:  2006-03-21       Impact factor: 25.391

7.  Individual physician practice variation in hematopoietic cell transplantation.

Authors:  Stephanie J Lee; Steven Joffe; Andrew S Artz; Richard E Champlin; Stella M Davies; Madan Jagasia; Nancy A Kernan; Fausto R Loberiza; Robert J Soiffer; Mary Eapen
Journal:  J Clin Oncol       Date:  2008-03-31       Impact factor: 44.544

8.  Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.

Authors:  Yi-Bin Chen; Tracy Batchelor; Shuli Li; Ephraim Hochberg; Mark Brezina; Sooae Jones; Candice Del Rio; Morgan Curtis; Karen K Ballen; Jeffrey Barnes; Andrew S Chi; Jorg Dietrich; Jessica Driscoll; Elizabeth R Gertsner; Fred Hochberg; Ann S LaCasce; Steven L McAfee; Thomas R Spitzer; Lakshmi Nayak; Philippe Armand
Journal:  Cancer       Date:  2014-09-09       Impact factor: 6.860

9.  Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.

Authors:  Brian C Shaffer; Kwang Woo Ahn; Zhen-Huan Hu; Taiga Nishihori; Adriana K Malone; David Valcárcel; Michael R Grunwald; Ulrike Bacher; Betty Hamilton; Mohamed A Kharfan-Dabaja; Ayman Saad; Corey Cutler; Erica Warlick; Ran Reshef; Baldeep Mona Wirk; Mitchell Sabloff; Omotayo Fasan; Aaron Gerds; David Marks; Richard Olsson; William Allen Wood; Luciano J Costa; Alan M Miller; Jorge Cortes; Andrew Daly; Tamila L Kindwall-Keller; Rammurti Kamble; David A Rizzieri; Jean-Yves Cahn; Robert Peter Gale; Basem William; Mark Litzow; Peter H Wiernik; Jane Liesveld; Bipin N Savani; Ravi Vij; Celalettin Ustun; Edward Copelan; Uday Popat; Matt Kalaycio; Richard Maziarz; Edwin Alyea; Ron Sobecks; Steven Pavletic; Martin Tallman; Wael Saber
Journal:  J Clin Oncol       Date:  2016-04-04       Impact factor: 44.544

10.  Integrating Patient-Reported Outcome Measures into Routine Cancer Care: Cancer Patients' and Clinicians' Perceptions of Acceptability and Value.

Authors:  Angela Stover; Debra E Irwin; Ronald C Chen; Bhishamjit S Chera; Deborah K Mayer; Hyman B Muss; Donald L Rosenstein; Thomas C Shea; William A Wood; Jessica C Lyons; Bryce B Reeve
Journal:  EGEMS (Wash DC)       Date:  2015-10-29
View more
  3 in total

1.  Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis.

Authors:  William A Wood; Ruta Brazauskas; Zhen-Huan Hu; Hisham Abdel-Azim; Ibrahim A Ahmed; Mahmoud Aljurf; Sherif Badawy; Amer Beitinjaneh; Biju George; David Buchbinder; Jan Cerny; Laurence Dedeken; Miguel Angel Diaz; Cesar O Freytes; Siddhartha Ganguly; Usama Gergis; David Gomez Almaguer; Ashish Gupta; Gregory Hale; Shahrukh K Hashmi; Yoshihiro Inamoto; Rammurti T Kamble; Kehinde Adekola; Tamila Kindwall-Keller; Jennifer Knight; Lalit Kumar; Yachiyo Kuwatsuka; Jason Law; Hillard M Lazarus; Charles LeMaistre; Richard F Olsson; Michael A Pulsipher; Bipin N Savani; Kirk R Schultz; Ayman A Saad; Matthew Seftel; Sachiko Seo; Thomas C Shea; Amir Steinberg; Keith Sullivan; David Szwajcer; Baldeep Wirk; Jean Yared; Agnes Yong; Jignesh Dalal; Theresa Hahn; Nandita Khera; Carmem Bonfim; Yoshiko Atsuta; Wael Saber
Journal:  Biol Blood Marrow Transplant       Date:  2018-03-19       Impact factor: 5.742

2.  Alignment of practices for data harmonization across multi-center cell therapy trials: a report from the Consortium for Pediatric Cellular Immunotherapy.

Authors:  Hisham Abdel-Azim; Hema Dave; Kimberly Jordan; Stephanie Rawlings-Rhea; Annie Luong; Ashley L Wilson
Journal:  Cytotherapy       Date:  2021-10-26       Impact factor: 5.414

3.  Translation of Clinical Research into Practice: An Impact Assessment of the Results from the Blood and Marrow Transplant Clinical Trials Network Protocol 0201 on Unrelated Graft Source Utilization.

Authors:  Nandita Khera; Lih-Wen Mau; Ellen M Denzen; Christa Meyer; Kate Houg; Stephanie J Lee; Mary M Horowitz; Linda J Burns
Journal:  Biol Blood Marrow Transplant       Date:  2018-06-30       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.